List of Excipients in Branded Drug DROXIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	DROXIA	hydroxyurea	0003-6336	CITRIC ACID MONOHYDRATE
ER Squibb & Sons LLC	DROXIA	hydroxyurea	0003-6336	D&C RED NO. 28
ER Squibb & Sons LLC	DROXIA	hydroxyurea	0003-6336	D&C RED NO. 33

Droxia Excipient Strategy and Commercial Opportunities in Hydroxyurea Capsules

Last updated: August 2, 2026

Droxia is an oral hydroxyurea capsule approved for adults with sickle-cell anemia to reduce the frequency of painful crises and the need for blood transfusions. Its commercial value is driven less by proprietary excipients than by dosage flexibility, safe handling of a cytotoxic active ingredient, pediatric administration, adherence, and reliable supply. The main opportunity is to develop differentiated hydroxyurea dosage forms that improve low-dose accuracy, swallowing, stability, and caregiver handling without creating unnecessary regulatory or bioequivalence risk.

What is Droxia and how is it regulated?

Droxia contains hydroxyurea, an antimetabolite that increases fetal hemoglobin in patients with sickle-cell anemia. The product is supplied in 200 mg, 300 mg, and 400 mg capsules. The U.S. Food and Drug Administration approved Droxia under NDA 020972 in 1998. The labeled indication is reduction of the frequency of painful crises and reduction of the need for blood transfusions in adults with sickle-cell anemia, with or without an increase in fetal hemoglobin levels.[1]

Hydroxyurea is also marketed in other products, including Hydrea and generic hydroxyurea capsules. Droxia is therefore part of a mature multisource market rather than a protected new-molecular-entity franchise.

Product attribute	Droxia position
Active ingredient	Hydroxyurea
Dosage form	Oral hard capsule
Strengths	200 mg, 300 mg, 400 mg
FDA application	NDA 020972
Initial U.S. approval	1998
Primary indication	Sickle-cell anemia
Therapeutic category	Antimetabolite; sickle-cell disease therapy
Key handling issue	Cytotoxic and potentially hazardous drug
Biosimilar pathway	Not applicable
Likely competitive pathways	ANDA, 505(b)(2), compounded or pharmacy-prepared liquid products

The FDA label requires blood-count monitoring and dose modification for myelosuppression. It also warns that hydroxyurea can cause severe anemia, neutropenia, thrombocytopenia, and other toxicities.[1] These clinical requirements affect the commercial design of any alternative dosage form.

What excipients are used in Droxia capsules?

Droxia’s labeled inactive ingredients include anhydrous lactose and sodium stearyl fumarate. The capsule shell contains gelatin and titanium dioxide, with colorants used to distinguish capsule strengths.[1]

Excipient or component	Function in the dosage form	Commercial relevance
Anhydrous lactose	Diluent and capsule-fill carrier	Cost-efficient, established, but relevant to lactose intolerance and formulation compatibility
Sodium stearyl fumarate	Lubricant	Alternative to magnesium stearate; can support capsule-fill processing
Gelatin	Hard capsule shell	Standard immediate-release shell; animal-origin and supply-chain considerations apply
Titanium dioxide	Opacifier and colorant	Regulatory and market-preference considerations vary by jurisdiction
Capsule colorants	Strength identification	Important for medication-error reduction and product differentiation

The excipient system is conventional. No Droxia-specific excipient appears to create a defensible exclusivity barrier by itself. The principal formulation barrier is the need to demonstrate consistent hydroxyurea content, dissolution, stability, capsule integrity, and safe manufacturing controls.

What excipient strategy best fits a Droxia generic?

A conventional capsule strategy has the lowest regulatory and development risk. A generic manufacturer can target the reference product’s composition and performance using anhydrous lactose, sodium stearyl fumarate, gelatin, and comparable capsule colorants. This approach is appropriate when the objective is rapid ANDA development and low manufacturing cost.

A differentiated excipient strategy should address a defined clinical or operational problem:

Low-dose accuracy

Sickle-cell disease therapy is weight-based and may require dose adjustments. The 200 mg capsule is not always sufficient for precise pediatric or low-weight dosing. A lower-strength capsule, multiparticulate product, scored tablet, or liquid formulation could improve dose flexibility.

The primary technical risks are content uniformity and dose segregation. Hydroxyurea must be uniformly distributed in the fill blend, and manufacturing controls must prevent potency variation between units.

Pediatric administration

Children may have difficulty swallowing capsules. An oral liquid, powder for reconstitution, dispersible tablet, or sprinkle formulation could address this limitation. The commercial opportunity is strongest where the product can provide stable, measurable dosing without requiring caregivers to manipulate a cytotoxic capsule.

A liquid formulation would require substantial work on:

• Hydroxyurea solubility and chemical stability
• Preservative selection
• Container compatibility
• Dose-measurement accuracy
• In-use stability after opening
• Protection from accidental caregiver exposure
• Microbiological quality
• Palatability

A ready-to-use liquid would have a stronger convenience proposition than a pharmacy-compounded suspension, but it would also face greater stability and regulatory requirements.

Safer handling

Hydroxyurea is classified as a hazardous drug in healthcare handling guidance. NIOSH identifies hazardous drugs based on carcinogenicity, reproductive toxicity, organ toxicity, or other hazard criteria.[2] Excipients cannot eliminate the hazard posed by hydroxyurea, but packaging and dosage-form design can reduce exposure.

Potential commercial features include unit-dose blister packaging, child-resistant closures, low-dust granules, tamper-evident packaging, and formulations that minimize capsule opening. These attributes are more likely to generate defensible product differentiation through packaging, device, or method patents than through the use of a conventional lubricant or filler.

What formulations are protected by Droxia patents?

Publicly available product information does not establish a meaningful active Droxia-specific patent estate covering the conventional capsule excipients. Hydroxyurea was disclosed and used clinically well before Droxia’s approval, and the original product’s commercial protection is not equivalent to current patent protection.

Patent risk should be separated into four categories:

Patent category	Droxia relevance	Commercial implication
Hydroxyurea compound patents	Historic and expired in practical terms	No meaningful compound barrier
Droxia capsule formulation patents	No clear current barrier established from the product label	Conventional generic development remains commercially viable
Method-of-use patents	Possible for particular sickle-cell populations or dosing regimens	Must be reviewed claim by claim
Packaging, liquid, pediatric, or handling patents	Potentially relevant to differentiated products	Could create narrower, product-specific barriers

An excipient supplier should not assume that matching Droxia’s inactive ingredients creates freedom to operate. Patent clearance should cover the final dosage form, manufacturing process, container closure, pediatric dosing method, and any delivery system. Excipient composition alone is unlikely to provide significant protection unless the formulation has a specific stability, dissolution, or handling advantage that is claimed and supported by data.

When did Droxia lose exclusivity?

Droxia’s original regulatory exclusivity and any meaningful original-product patent protection have expired. The product is now exposed to generic competition. FDA’s Orange Book should be used to confirm current patent and exclusivity entries for NDA 020972 because listings can change over time.[3]

Hydroxyurea capsules are not eligible for biosimilar competition because hydroxyurea is a small-molecule drug, not a biologic. Competition proceeds through abbreviated new drug applications, traditional NDAs, or alternative regulatory routes.

Exclusivity issue	Droxia assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	No current Droxia exclusivity barrier identified
Pediatric exclusivity	No current barrier identified
Active Orange Book patent barrier	Requires current FDA Orange Book verification
Generic entry	Legally feasible, subject to product-specific approval
Biosimilar entry	Not applicable

What is the Orange Book status of Droxia?

Droxia is listed as an NDA product rather than an ANDA generic. Orange Book patent listings must be assessed at the application level, including any listed patents, expiration dates, and pediatric exclusivity information.[3]

A product-level review should verify:

1. Whether NDA 020972 remains listed as marketed.
2. Whether any patents are currently listed.
3. Whether any patent use codes cover the labeled indication.
4. Whether an applicant would need a Paragraph IV certification.
5. Whether the reference product is eligible for a suitability petition or requires a different ANDA strategy.

A Paragraph IV challenge would be relevant only if an unexpired Orange Book patent were listed. For a mature hydroxyurea capsule product, the commercial value of a Paragraph IV strategy is likely lower than the value of differentiated dosage-form development unless a current listed patent creates a meaningful launch opportunity.

What generic entry risks exist for Droxia?

The largest risks are technical and commercial rather than compound-patent risks.

Bioequivalence and product performance

A conventional immediate-release capsule may qualify for an ANDA if the proposed product meets FDA requirements for pharmaceutical equivalence and bioequivalence. Differences in excipient grade, capsule shell, fill weight, lubricant level, or manufacturing process can affect dissolution and content uniformity.

Hazardous-drug manufacturing

Manufacturers must control worker exposure, cross-contamination, cleaning validation, and waste handling. These requirements can increase capital and operating costs compared with ordinary oral solid products.[2]

Small market size

Sickle-cell disease has a substantial treatment need, but the Droxia segment is narrower than major cardiovascular, metabolic, or central nervous system markets. A generic capsule manufacturer may face limited volume, price compression, and supply obligations.

Clinical dosing complexity

Hydroxyurea requires laboratory monitoring and dose adjustment. A product that improves dose flexibility may gain use in pediatric and specialty-care settings, but it must preserve accurate dosing and avoid medication errors.

Reimbursement and channel concentration

Hydroxyurea is distributed through retail pharmacies, specialty pharmacies, health systems, and public-health programs. Contracting and formulary access can matter more than minor excipient differences.

Which excipient opportunities have the strongest commercial potential?

The strongest opportunities are products that solve an administration or supply problem.

Opportunity	Excipient or formulation focus	Commercial assessment
Lower-strength capsule	Fill-weight and content-uniformity optimization	Moderate opportunity; improves dose flexibility
Oral liquid	Solubilizer, buffer, preservative, viscosity modifier	High unmet-use potential, higher development risk
Powder for reconstitution	Wetting, suspending, and flavor-masking system	Moderate to high; may improve shelf life and transport
Sprinkle formulation	Multiparticulate coating and taste masking	Moderate; useful for children unable to swallow capsules
Gluten-free or lactose-free capsule	Alternative diluent system	Limited differentiation but useful for specific patients
Vegetarian capsule	Hypromellose or pullulan shell	Marketing and supply-chain benefit, limited clinical differentiation
Unit-dose hazardous-drug packaging	Blister, barrier film, and child-resistant closure	Strong operational value; protection may be packaging-based
Compounded-liquid replacement	Ready-to-use or stable reconstituted product	Strongest clinical-commercial opportunity

A lactose-free formulation could address patient preference and simplify positioning, but lactose in a capsule-fill formulation is not necessarily a clinical limitation for most patients. It is therefore more likely to be a secondary marketing attribute than a primary basis for premium pricing.

How does Droxia compare with competing hydroxyurea products?

Droxia competes with generic hydroxyurea capsules and other hydroxyurea products rather than with biosimilars or directly substitutable biologic therapies. The primary points of competition are price, strength availability, supply reliability, capsule identification, and ease of administration.

Competitive dimension	Droxia	Generic hydroxyurea capsules	Differentiated liquid or pediatric product
Regulatory pathway	NDA	ANDA	ANDA or 505(b)(2), depending on differences
Dosage flexibility	200-400 mg strengths	Varies by manufacturer	Potentially high
Pediatric usability	Limited	Usually limited	Strong
Excipient differentiation	Low	Usually low	Potentially high
Hazard-handling improvement	Primarily packaging-dependent	Manufacturer-dependent	Potentially high
Price position	Reference-product or branded position	Low-price position	Premium or specialty position possible
Patent opportunity	Limited conventional-capsule opportunity	Limited	Greater formulation and device opportunity

A 505(b)(2) application may be appropriate for a liquid or novel delivery system that relies partly on FDA’s prior findings for hydroxyurea but differs materially from the reference product. The route may require additional clinical, stability, safety, or bridging data.

What licensing deals could support a Droxia excipient program?

The most relevant licensing targets are not traditional pharmaceutical compound licenses. They are technology and supply agreements covering:

• Pediatric liquid vehicles
• Taste-masking systems
• Low-dust hazardous-drug processing
• Unit-dose blister packaging
• Hypromellose or other non-gelatin capsule shells
• Stability-enhancing container-closure systems
• Specialized manufacturing for cytotoxic or hazardous oral solids

An excipient supplier could pursue a co-development structure with a generic manufacturer, specialty pharmacy, or hospital-focused drug developer. The commercial model could include formulation licensing, preferred-supplier status, technology transfer fees, or a supply agreement tied to approved product volume.

The value of a licensing deal would depend on whether the technology produces a measurable regulatory, manufacturing, or clinical advantage. A standard lactose or lubricant supply agreement is unlikely to justify substantial upfront economics.

What patent litigation affects Droxia?

No major current patent-litigation barrier can be established from the product label alone. Historic litigation involving hydroxyurea products, generic approvals, or sickle-cell treatment patents should be distinguished from current Droxia-specific litigation.

For a new formulation, litigation exposure would more likely involve:

• Pediatric hydroxyurea liquids
• Stable liquid compositions
• Taste-masked multiparticulates
• Low-dose hydroxyurea delivery
• Hazardous-drug packaging
• Dosing methods for defined patient populations
• Manufacturing processes that improve content uniformity or stability

A generic capsule applicant should review FDA Orange Book listings, patent-family status in the United States, and litigation records under the Hatch-Waxman framework before filing. A differentiated formulation should conduct a broader freedom-to-operate analysis covering formulation, process, packaging, and method claims.

What is the revenue opportunity for Droxia excipient innovation?

Product-level Droxia revenue is not reliably disclosed as a standalone figure in public company reporting. The addressable opportunity is better assessed through market structure:

1. Generic capsule volume is likely to be price-sensitive.
2. Conventional excipient substitution is unlikely to support a material premium.
3. Pediatric and liquid formulations can access unmet administration needs.
4. Packaging and handling improvements may support institutional and specialty-pharmacy contracts.
5. Reliable supply of hydroxyurea products has strategic value because treatment interruption can create clinical risk.

The highest-value opportunity is a complete dosage-form platform rather than a single excipient. A stable, accurately measurable, caregiver-friendly liquid or low-dose multiparticulate product could command stronger commercial positioning than a lactose-free or color-matched capsule.

Key Takeaways

• Droxia is a mature hydroxyurea capsule product with no meaningful compound-exclusivity barrier.
• Its labeled excipients are conventional: anhydrous lactose, sodium stearyl fumarate, gelatin, titanium dioxide, and capsule colorants.
• Excipients alone are unlikely to create substantial commercial differentiation in a standard capsule.
• The strongest opportunities are pediatric liquids, lower-dose products, sprinkle formulations, and hazardous-drug packaging.
• Generic entry is primarily constrained by bioequivalence, content uniformity, stability, manufacturing controls, and market size.
• Biosimilar competition does not apply.
• Any current Paragraph IV or Orange Book strategy requires application-specific FDA verification.
• A differentiated hydroxyurea formulation may be better suited to a 505(b)(2) strategy than a conventional ANDA.
• Licensing value is highest for pediatric delivery, taste masking, low-dust processing, and unit-dose packaging technologies.

FAQs

Can lactose be removed from a generic Droxia formulation?

Yes. A manufacturer could develop a lactose-free capsule using another diluent, but the change would require formulation development and regulatory demonstration of equivalent quality and performance.

Is sodium stearyl fumarate essential to Droxia manufacturing?

No. It is a formulation lubricant, not the active ingredient. Other lubricants may be technically feasible, subject to compatibility, dissolution, content uniformity, and regulatory requirements.

Can hydroxyurea be sold as a pediatric liquid?

A pediatric liquid can be developed, but stability, preservative effectiveness, dose accuracy, palatability, container compatibility, and hazardous-drug handling must be addressed. The regulatory pathway depends on the extent of formulation and labeling differences.

Would a vegetarian capsule create patent protection?

A vegetarian capsule shell alone would rarely create meaningful patent protection. Stronger protection would require a defined composition or manufacturing feature that provides a demonstrated technical advantage.

Is a pharmacy-compounded hydroxyurea suspension a direct substitute for Droxia?

It may be used when an appropriate commercial dosage form is unavailable, but compounded products can differ in stability, concentration, preparation controls, labeling, and quality assurance. A commercially approved liquid could compete by offering standardized manufacturing and shelf-life data.

References

1. U.S. Food and Drug Administration. (n.d.). Droxia (hydroxyurea) capsules: Prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. National Institute for Occupational Safety and Health. (2016). NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. Centers for Disease Control and Prevention. https://www.cdc.gov/niosh/docs/2016-161/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files-vesm